Myesha Lacy

Myesha joined Arcellx in June 2021, bringing over 25 years of experience as a communications professional experienced in providing strategy, development, and execution of internal and external communications programs, for publicly traded pharmaceutical and biotechnology companies. Most recently, Myesha was Vice President, Investor Relations and Corporate Communications at Adverum Biotechnologies. Prior to, Myesha held the same role at Global Blood Therapeutics, Inc., a $3 billion market capitalization company. Previously, Myesha led the integrated communications function at ZS Pharma, Inc. (acquired by AstraZeneca PLC), Hyperion Therapeutics, Inc. (acquired by Horizon Pharma), and served in various communications roles with increasing responsibility at other publicly traded biotechnology companies. Myesha earned a B.A. in Business from Holy Names University.